$2.48
+0.25
(+11.21%)▲
Insights on Omega Therapeutics
Revenue is up for the last 4 quarters, 516.0K → 989.0K (in $), with an average increase of 18.9% per quarter
Netprofit is up for the last 3 quarters, -29.68M → -20.21M (in $), with an average increase of 21.8% per quarter
In the last 1 year, Novo Nordisk A/s has given 54.6% return, outperforming this stock by 125.0%
9.27%
Downside
Day's Volatility :13.13%
Upside
4.25%
47.58%
Downside
52 Weeks Volatility :87.12%
Upside
75.42%
Period | Omega Therapeutics | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -28.74% | -1.0% | 0.0% |
6 Months | 37.78% | 10.9% | 0.0% |
1 Year | -70.37% | 5.2% | 2.1% |
3 Years | -84.5% | 15.9% | -21.9% |
Market Capitalization | 129.6M |
Book Value | $1.05 |
Earnings Per Share (EPS) | -1.8 |
Wall Street Target Price | 11.83 |
Profit Margin | 0.0% |
Operating Margin TTM | -2092.92% |
Return On Assets TTM | -35.77% |
Return On Equity TTM | -118.82% |
Revenue TTM | 3.1M |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | 34.599999999999994% |
Gross Profit TTM | -74.0M |
EBITDA | -98.7M |
Diluted Eps TTM | -1.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -1.21 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | -0.42 |
What analysts predicted
Upside of 377.02%
Sell
Neutral
Buy
Omega Therapeutics is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Omega Therapeutics | -17.61% | 37.78% | -70.37% | -84.5% | -84.5% |
Moderna, Inc. | 7.58% | 56.48% | -15.18% | -40.08% | 293.3% |
Regeneron Pharmaceuticals, Inc. | -5.36% | 10.34% | 13.15% | 84.9% | 169.37% |
Novo Nordisk A/s | 2.17% | 28.02% | 54.56% | 243.01% | 428.79% |
Vertex Pharmaceuticals Incorporated | -1.78% | 6.8% | 16.22% | 84.51% | 137.19% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Omega Therapeutics | NA | NA | NA | -1.15 | -1.19 | -0.36 | NA | 1.05 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Omega Therapeutics | Buy | $129.6M | -84.5% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 293.3% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 169.37% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 428.79% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 137.19% | 28.81 | 36.68% |
Flagship Ventures Management, Inc.
FMR Inc
Harbourvest Partners, LLC
State Of Wisconsin Investment Board
Vanguard Group Inc
BlackRock Inc
Omega Therapeutics’s price-to-earnings ratio stands at None
Read Moreomega therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. the company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. we are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines
Organization | Omega Therapeutics |
Employees | 93 |
CEO | Mr. Mahesh Karande |
Industry | Services |
One Group Hospitality Inc/th
$2.48
+11.21%
Kura Sushi Usa Inc-class A
$2.48
+11.21%
Iheartmedia
$2.48
+11.21%
Hireright Holdings Corp.
$2.48
+11.21%
Barrett Business Services Inc
$2.48
+11.21%
Ikena Oncology Inc
$2.48
+11.21%
Sonder Holdings Inc
$2.48
+11.21%
Noodles & Co
$2.48
+11.21%
D-market Electronic Services
$2.48
+11.21%